NCT04737928Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)

N/A

Standard of Care Imaging

Uveitis

N/A

Clinical Trials (1)

NCT04704609Imaging Quantification of Inflammation (IQI)

N/A

Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients

Primary Open-angle Glaucoma

N/A

Clinical Trials (1)

NCT04609345Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients

N/A

Diquafosol

Dry Eye

N/A

Clinical Trials (1)

NCT04952987Dry Eye Management With 3% Diquafosol Before and After Cataract Surgery

N/A

Microshunt XI

Primary Open Angle Glaucoma

N/A

Clinical Trials (1)

NCT07235592PRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group

N/A

A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sj

Dry Eye Syndromes

N/A

Clinical Trials (1)

NCT02011776A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome

N/A

Tafluprost, timolol maleate

Ocular Surface Disease

N/A

Clinical Trials (1)

NCT04828057Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting

N/A

Non-Intervention

Myopia

N/A

Clinical Trials (1)

NCT06912802Observational Survey Study on the Impact of Myopia and Its Complications on Quality of Life.

N/A

Preservative free tafluprost 0.0015% eye drops

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT01434888Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

Phase 1

Preservative free tafluprost opthalmic solution

Glaucoma

Phase 1

Clinical Trials (1)

NCT02102750A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension

Phase 1

NOVA63035 "Corticosteroid"

Diabetic Macular Edema

Phase 1

Clinical Trials (1)

NCT00665106Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Phase 1

STN1013800 ophthalmic solution

Blepharoptosis

Phase 1

Clinical Trials (1)

NCT06911216A Pharmacokinetics (PK) Study in Healthy Adults

Phase 1

Paroxetine

Healthy

Phase 1

Clinical Trials (1)

NCT00879099Interaction Study of Timolol Eye Drops and Paroxetine Capsules

Phase 1

Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

Dry Eye Disease

Phase 1

Clinical Trials (1)

NCT03216096Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

Phase 1

DE-117

Healthy Male Adults

Phase 1

Clinical Trials (1)

NCT02650063A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -

Phase 1

STN1012600 ophthalmic solution 0.002%

Healthy Adult Males Volunteers

Phase 1

Clinical Trials (1)

NCT05905653Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Phase 1

MS-R001

Diabetic Macular Edema

Phase 1

Clinical Trials (1)

NCT00401115Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

Phase 1

0.5 mg of DE-122

Age-Related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT02555306A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration

Phase 1/2

Levofloxacin Ophthalmic

Endophthalmitis Postoperative

Phase 1/2

Clinical Trials (1)

NCT04212078Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime

Phase 1/2

Levofloxacin Ophthalmic Product

Endophthalmitis Postoperative

Phase 1/2

Clinical Trials (1)

NCT04212429The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Phase 1/2

DE-104 medium concentration

Open-Angle Glaucoma

Phase 1/2

Clinical Trials (1)

NCT00868894Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension

Phase 1/2

Sirolimus

Age-related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT00712491Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

Phase 1/2

DE-120

Age-Related Macular Degeneration

Phase 1/2

Clinical Trials (1)

NCT02022501A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Phase 1/2

DE-101 ophthalmic suspension

Dry Eye

Phase 1/2

Clinical Trials (1)

NCT01118754Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Phase 1/2

Levofloxacin Ophthalmic Solution

Endophthalmitis

Phase 1/2

Clinical Trials (1)

NCT04214821The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Phase 1/2

DE-112

Open-angle Glaucoma

Phase 1/2

Clinical Trials (1)

NCT01279083Safety and Efficacy Trial to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 1/2

DE-117

Glaucoma and Ocular Hypertension

Phase 1/2

Clinical Trials (1)

NCT01654484A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Phase 1/2

STN1010904 ophthalmic suspension 0.03% BID

Fuchs Endothelial Corneal Dystrophy

Phase 2

Clinical Trials (1)

NCT05376176A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

Phase 2

Diquafosol sodium 3%

Dry Eye Disease

Phase 2

Clinical Trials (1)

NCT06146881Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia

Phase 2

Sirolimus

Dry Eye

Phase 2

Clinical Trials (1)

NCT00814944A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) Model

Phase 2

Latanoprost

Glaucoma

Phase 2

Clinical Trials (1)

NCT01254370Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease

Phase 2

DE-104 ophthalmic solution

Open-Angle Glaucoma

Phase 2

Clinical Trials (1)

NCT00656240To Investigate the Safety and Efficacy of DE-104 Ophthalmic Solution to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2

DE-105 ophthalmic solution

Persistent Corneal Epithelial Defect

Phase 2

Clinical Trials (1)

NCT00988494Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Phase 2

DE-120

Age-Related Macular Degeneration

Phase 2

Clinical Trials (1)

NCT02401945A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

Phase 2

DE-126 Ophthalmic Solution 0.002% QD

Primary Open Angle Glaucoma

Phase 2

Clinical Trials (1)

NCT04742283Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 2

Sirolimus

Geographic Atrophy

Phase 2

Clinical Trials (1)

NCT01675947Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

Phase 2

DE-089 ophthalmic solution

Dry Eye

Phase 2

Clinical Trials (1)

NCT01189032Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Phase 2

DE-117 ophthalmic solution

Open-angle Glaucoma or Ocular Hypertension

Phase 2

Clinical Trials (1)

NCT01868126Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 2

DE-117 Ophthalmic Solution QD

Primary Open-angle Glaucoma and Ocular Hypertension

Phase 2

Clinical Trials (1)

NCT03858894Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6

Phase 2

DE-110 ophthalmic suspension high dose

Dry Eye

Phase 2

Clinical Trials (1)

NCT01239069Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Phase 2

DE-104 ophthalmic solution, low concentration

Open-Angle Glaucoma

Phase 2

Clinical Trials (1)

NCT00650338Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension